Bio-Rad Laboratories, Inc. (BIO.B) Stock Score, Valuation & Financial Research
Bio-Rad Laboratories, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 35/100.
Quick answer for BIO.B
Bio-Rad Laboratories, Inc. currently has a Wall Street Score of 35/100. The stored market price is $365.08. Its financial score is 32/100. Its valuation score is 4/100. The latest WSS change is +0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What Bio-Rad Laboratories, Inc. does
Bio-Rad Laboratories, Inc. creates, manufactures, and markets products essential for life science research and clinical diagnostics. Its operations span globally, covering territories such as the United States, Europe, Asia, Canada, and Latin America. The company's business is organized into two main divisions: Life Science and Clinical Diagnostics. The Life Science division develops and provides a comprehensive array of reagents, laboratory apparatus, and instruments. These are vital for various applications, including scientific research methodologies, biopharmaceutical production processes, and food quality testing. This segment dedicates its efforts to key areas within the life sciences, such as proteomics, genomics, biopharmaceutical development, cellular biology, and ensuring food safety. Its diverse clientele includes academic institutions (universities and medical schools), indus
BIO.B financial snapshot
- Wall Street Score:
- 35/100
- Current price:
- $365.08
- Market capitalization:
- $9.99B
- Revenue:
- $2.59B
- Net income:
- $222.4M
- Free cash flow:
- $374.6M
- Cash:
- $517.0M
- Total debt:
- $1.20B
- EPS:
- 8.33
- P/E ratio:
- 43.8x
- Financial score:
- 32/100
- Valuation score:
- 4/100
- Revenue score:
- 9/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $374.6M, showing positive cash generation.
- The balance sheet shows $517.0M of cash versus $1.20B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.2 points: BIO.B increased 0.2 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 4/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 32/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BIO.B
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.